Dramatic Response of S-1 Administration to Chemorefractory Advanced Thymic Cancer

Publisher： Karger

E-ISSN： 1421-9794|60|5-6|356-359

ISSN： 0009-3157

Source： Chemotherapy, Vol.60, Iss.5-6, 2015-0, pp. : 356-359

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Retrospective Study of the Novel Combination of Paclitaxel and S1 for Pretreated Advanced Non-Small Cell Lung Cancer

By  

Chemotherapy, Vol. 58, Iss. 6, 2013-01 ,pp. : 454-460

Karger

Access to resources Recommend Favorite

A Phase II Study of S-1 for Previously Untreated Elderly Patients with Advanced Non-Small Cell Lung Cancer

By  

Chemotherapy, Vol. 61, Iss. 2, 2015-0 ,pp. : 93-98

Karger

Access to resources Recommend Favorite

New Perspectives in the Treatment of Advanced Gastric Cancer: S-1 as a Novel Oral 5-FU Therapy in Combination with Cisplatin

By  

Chemotherapy, Vol. 62, Iss. 1, 2016-09 ,pp. : 62-70

Karger

Access to resources Recommend Favorite

Phase I/II Trial of Irinotecan and S-1 Combination Chemotherapy as a Second-Line Treatment for Advanced Colorectal Cancer

By  

Chemotherapy, Vol. 59, Iss. 5, 2014-05 ,pp. : 338-343

Karger

Access to resources Recommend Favorite

Phase I Study of S-1 plus Nedaplatin in Patients with Advanced/Recurrent Head and Neck Cancer

By  

Chemotherapy, Vol. 56, Iss. 6, 2010-11 ,pp. : 453-458

Karger

Access to resources Recommend Favorite